Devansh Mishra’s Latest Research Highlights Hypercoagulable State in COPD
Devansh Mishra, Associate at Trainee Research AssoCiation of KGMU (TRACK), shared a post on LinkedIn:
“New Publication Alert!
Thrilled to share our latest research article, “Evaluation of Prothrombotic Biomarkers in Stable and Exacerbation Phases of Chronic
Obstructive Pulmonary Disease: A Cross-Sectional Study,” published in Cureus.
Chronic Obstructive Pulmonary Disease (COPD) remains a major global health burden, and acute exacerbations (AECOPD) significantly worsen morbidity and mortality. Our study explores the role of prothrombotic biomarkers—fibrinogen, CRP, D-dimer, and vWF—in identifying and differentiating stable and exacerbation phases of COPD.
We found that AECOPD is associated with a distinct hypercoagulable state, emphasizing the growing evidence that inflammation and thrombosis are tightly linked in disease progression. These findings not only shed light on potential diagnostic and prognostic biomarkers but also open pathways for early risk stratification and targeted therapy.
Grateful to my mentors Prof. Virendra Atam sir, Prof. Shyam chand Chaudhary sir, and Dr. Jay Tewari boss for their invaluable guidance and support throughout this work.
Proud to contribute to the evolving understanding of COPD pathophysiology and its clinical management.”
Title: Evaluation of Prothrombotic Biomarkers in Stable and Exacerbation Phases of Chronic Obstructive Pulmonary Disease: A Case-Control Study
Authors: Kamlesh K. Gupta, Shantanu Singh, Virendra Atam, Devansh Mishra, Jay Tewari, Shyam C. Chaudhary, Ajay Patwa
Read full article here
Stay updated with Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 15:10David McIntosh Reflects on International Plasma Awareness Week
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation